ASND
Ascendis Pharma·NASDAQ
--
--(--)
--
--(--)
ASND fundamentals
Ascendis Pharma (ASND) released its earnings on Feb 11, 2026: revenue was 291.19M (YoY +61.74%), beat estimates; EPS was -0.65 (YoY +1.89%), missed estimates.
Revenue / YoY
291.19M
+61.74%
EPS / YoY
-0.65
+1.89%
Report date
Feb 11, 2026
ASND Earnings Call Summary for Q4,2025
- Revenue Growth: YORVIPATH (EUR 477M/2025) and SKYTROFA (EUR 206M/2025) drove top-line performance, with 2026 targeting EUR 500M operating cash flow.
- Pipeline Momentum: TransCon CNP FDA approval expected in late Feb 2026; Phase II combo trial for achondroplasia showed 3-4x linear growth improvement.
- Strategic Expansion: 10 new YORVIPATH launches in 2026; 2030 goal of EUR 5B annual revenue via label expansion and new indications.
- Competitive Edge: CEO dismissed competitors' approaches, highlighting Ascendis' hormone replacement therapy as superior to nonspecific kinase inhibitors.
EPS
Actual | -1.4484 | -2.2126 | -2.7088 | -3.2791 | -1.3751 | -2.9648 | -1.7022 | -2.1142 | -2.4455 | -1.5301 | -3.043 | -3.9599 | -2.1459 | -2.356 | -2.8435 | -1.6998 | -2.4817 | -2.0458 | -1.9151 | -0.6625 | -1.7093 | -0.966 | -1.1734 | -0.65 | |||||||||||
Forecast | -1.4607 | -1.6442 | -1.8466 | -1.9226 | -2.1333 | -2.6446 | -2.6704 | -2.6178 | -2.2772 | -2.2676 | -2.4922 | -2.8358 | -2.8805 | -2.7516 | -2.5081 | -2.0029 | -1.5936 | -1.5621 | -1.7422 | -1.0192 | -1.5874 | -1.5148 | -0.2865 | -0.2246 | |||||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +0.84% | -34.57% | -46.69% | -70.56% | +35.54% | -12.11% | +36.26% | +19.24% | -7.39% | +32.52% | -22.10% | -39.64% | +25.50% | +14.38% | -13.37% | +15.13% | -55.73% | -30.96% | -9.92% | +35.00% | -7.68% | +36.23% | -309.56% | -189.40% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 2.44M | 1.61M | 3.23M | 639.92K | 876.77K | 1.21M | 1.29M | 5.56M | 7.56M | 6.46M | 15.36M | 24.10M | 36.40M | 51.69M | 47.43M | 151.99M | 103.47M | 38.56M | 64.39M | 180.04M | 109.22M | 186.18M | 250.69M | 291.19M |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 2.33M | 2.45M | 1.63M | 2.07M | 1.93M | 885.68K | 1.32M | 3.07M | 5.03M | 5.85M | 8.61M | 20.61M | 23.39M | 40.61M | 51.72M | 103.14M | 85.77M | 88.87M | 78.29M | 123.91M | 102.62M | 169.62M | 250.22M | 288.45M |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +4.74% | -34.26% | +97.83% | -69.10% | -54.61% | +36.84% | -2.37% | +81.04% | +50.13% | +10.27% | +78.40% | +16.95% | +55.67% | +27.29% | -8.31% | +47.36% | +20.63% | -56.61% | -17.75% | +45.30% | +6.43% | +9.76% | +0.19% | +0.95% |
Earnings Call
You can ask Aime
What is Ascendis Pharma's latest dividend and current dividend yield?What guidance did Ascendis Pharma's management provide for the next earnings period?What is the revenue and EPS growth rate for Ascendis Pharma year over year?What is the market's earnings forecast for Ascendis Pharma next quarter?What does Ascendis Pharma do and what are its main business segments?Did Ascendis Pharma beat or miss consensus estimates last quarter?What factors drove the changes in Ascendis Pharma's revenue and profit?What were the key takeaways from Ascendis Pharma’s earnings call?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
